651734-52-0

Basic information

• Product Name: 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid
• Synonyms: 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid
• CAS NO: 651734-52-0
• Molecular Formula: C₁₆H₁₅F₂NO₄
• Molecular Weight: 323.2914064
• Mol File: 651734-52-0.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid(651734-52-0)
• EPA Substance Registry System: 4-(Benzylamino)-3,5-difluoro-2,6-dimethoxybenzoic acid(651734-52-0)

Safety Data

• Hazardous Substances Data: 651734-52-0(Hazardous Substances Data)

Upstream product

• 651734-51-9 methyl 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoate 
• 122590-82-3 methyl N-benzyl-4-amino-2,3,5,6-tetrafluorobenzoate 
• 124-41-4 sodium methylate 
• 36629-42-2 methyl pentafluorobenzoate 
• 602-94-8 Pentafluorobenzoic acid 

Downstream Products

• 1513857-77-6 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3’,2’:5,6]pyrido[4,3-d]pyrimidin-2-one 
• 651734-54-2 2,6-difluoro-3,5-dimethoxybenzeneamine 
• 651734-51-9 methyl 4-(benzylamino)-3,5-difluoro-2,6-dimethoxybenzoate 

Relevant articles and documents

DERIVATIVES OF AN FGFR INHIBITOR

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS

This invention provides methods for utilizing compounds that inhibit cyclin-dependent kinase and tyrosine kinase enzymes in the promotion of neochondrogenesis and the enhancement, protection and repair of cartilage. In certain embodiments the invention relates to methods of using compounds of formula (I): and pharmaceutically acceptable salts thereof, to promote neochondrogenesis, wherein, R1,R2, R3, R4, R5, R6, A, B, D, and E have any of the values defined therefor in the specification.